Methods of detecting prostate cancer using BAP28-related biallelic markers
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 16, 2011
Grant Date -
Jul 10, 2008
app pub date -
Jul 12, 2007
filing date -
Jun 25, 1999
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention is directed to BAP28 polypeptides. BAP28 cDNA sequences encoding BAP28 polypeptides, to the genomic DNA sequence of the BAP28 gene as well as to regulatory regions located at the 5′- and 3′-ends of the BAP28 coding region. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the BAP28 gene useful in genetic analysis. The invention concerns an association of the BAP28-related biallelic markers with prostate cancer. Therefore, the invention contemplates the diagnostic and treatment methods of prostate cancer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully